In the medical field, the (also known as the CHERISH study ) was a critical Phase 3 clinical trial for Nusinersen (brand name Spinraza), a treatment for Spinal Muscular Atrophy (SMA).
The CS4 trial reported [number]% of patients in the treatment group achieved the primary outcome measure compared to [number]% in the control group (p < [p-value]). The study also found that [secondary outcome measures] were significantly improved in the treatment group compared to the control group. The study's results suggest that the new therapeutic approach is both safe and effective, with a favorable risk-benefit profile.
Pharmacokinetics of therapies approved for spinal muscular atrophy